Redcare Pharmacy Raises 2026 Revenue Guidance on Strong Rx Momentum in Germany

Redcare Pharmacy N.V. announced on September 28, 2026, that it is raising its full-year 2026 revenue guidance for the second time this year, citing continued strong momentum in prescription (Rx) revenue in Germany. The company now expects Rx revenue in Germany to reach EUR 730 to 760 million for full-year 2026, up from the previously guided range of EUR 680 to 720 million. This represents growth of 45% to 51%, compared to the prior guidance of 35% to 43%. Total revenue growth guidance for 2026 has also been increased to 16% to 18%, from 15% to 17% previously. Non-Rx growth guidance remains unchanged at 10% to 12%, and the adjusted EBITDA margin guidance is confirmed at between 2.5% and 3.0%.

The upgrade is driven by preliminary figures showing that Rx revenue in Germany grew by 51% year-on-year in September and 56% in the third quarter. September’s performance was particularly notable given a high comparison base from the prior year, when the current Rx bonus was introduced. “Our growth is backed by strong customer satisfaction: eRx NPS continues to rise, up 6 points year-on-year to 80 in August,” said Olaf Heinrich, CEO of Redcare Pharmacy. While Rx revenue remained strong throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. Based on preliminary figures, the adjusted EBITDA margin remained flat quarter-on-quarter, benefiting from continued operating leverage.

This news matters because it underscores the accelerating shift toward digital healthcare solutions in Europe, with Redcare Pharmacy at the forefront. The company, which generated EUR 2.9 billion in revenues in 2025, is the leading online pharmacy in Europe, active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands, and Switzerland. With over 14 million active customers and more than 500,000 healthcare-related products, Redcare offers a true one-stop pharmacy experience, including prescription drugs in Germany, Switzerland, and the Netherlands. The strong Rx momentum in Germany, Redcare’s largest market, highlights the growing acceptance of e-prescriptions and online pharmacy services among consumers and healthcare providers.

For Texas businesses and the broader healthcare industry, Redcare’s success demonstrates the potential of digital health platforms to drive significant revenue growth and operational efficiency. As Texas continues to embrace telemedicine and digital health innovations, the Redcare model could serve as a blueprint for companies looking to scale online pharmacy services. The company’s ability to maintain a flat adjusted EBITDA margin while growing revenue rapidly suggests that operating leverage can be achieved even in a high-growth phase, which is a valuable insight for investors and entrepreneurs. The full set of figures for the third quarter of 2026 will be shared on October 29, 2026, when the company hosts its quarterly conference call.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX. The original release can be viewed on www.newmediawire.com.